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Abstract 
Author: Katherine Banner 
Thesis: The Problem of the Neurodegenerative Germline: An Ethical Reconsideration in Light of 
Genetic Engineering Developments 
Supervising Professors: Dr. Joy Penticuff, Dr. Nancy Moran 
 
In this thesis I strive to answer the question, “Is it ethically justifiable to edit out the 
mutant Alzheimer’s gene, and therefore the germline of, a human embryo with the CRISPR-
Cas9 system?” 
 There are many risks of the CRISPR-Cas9 technology, including the off-target effects of 
mosaicism, unintended base changes, and double-stranded breaks. Along with this, using the 
CRISPR-Cas9 system on the germline of a human embryo violates the two major theories of 
bioethics as well as the principles of medical ethics. There is also a large public and religious 
fear about the clinical use of this technology. 
 Through the analysis of the science behind CRISPR-Cas9, the scientific benefits and 
risks of CRISPR-Cas9, and the medical ethics of its clinical use, I determined that it is not 
ethically justifiable to use CRISPR-Cas9 in its current state to edit the germline of a human 
embryo in order to remove Alzheimer’s disease. I also determined that it is not ethically 
justifiable to use CRISPR-Cas9 in a future, more accurate state unless multiple limitations and 
regulations on the technology are set. 
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I. Introduction 
 
Modern advancement in the scientific community has been astounding, and sometimes 
very unexpected. We have discovered smaller particles than ever before known, bioengineered 
body parts for humans, developed cures and vaccinations for diseases that we never thought 
would be possible, and so much more. Science is leading us, as humans, down a future path that 
nobody expected, and a path that some may not want. Some of these new scientific discoveries, 
especially the new technologies involving genetic engineering, could change the human race for 
the good and possibly for the bad. The possibility (and success) of editing the genomes of 
different organisms around the world, including humans, has recently come into light, and has 
proven to be one of the most significant and promising technologies in the scientific and medical 
communities today.  
However, the ethical dilemma that the new genetic engineering technologies has 
presented cannot be ignored. Whether these technologies should actually be used on the human 
population, and if so what they can and cannot be used for, is a question that can change the 
future of humans in innumerable ways. 
 There are many proposed uses of the new genetic engineering technologies, including 
cancer therapy and other therapies for genetic diseases. However, the ability to alter the human 
genome in any form raises many ethical concerns, as altering our genetic makeup can go much 
further than disease therapy. Altering the human genome would not only allow us to edit out 
mutant genes that cause disease in humans, but also to alter multiple other traits. We have 
already developed the technology to genetically test the genomes of human embryos (a human 
which is in the early stages of development and has not been born, and is derived from the 
zygote, which is the single cell resulting from the fertilization of an egg by a sperm) for their 
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genetic makeup (what genes they are positive for), and those who participate in in-vitro 
fertilization have the ability to take advantage of this technology. For example, parents are able 
to choose the sex of their child if they desire to. Any action similar to this introduces the ethical 
debate associated with genetic engineering: what should it be used for? There is a major fear of 
using the new genetic engineering technologies to perform similar actions and create “designer 
babies” or “genetically modified humans.”1 
The genetic engineering techniques we have developed involve the precise modification 
of DNA and allows genes to be turned on or off, meaning that certain genes will not be 
physically expressed if they are turned off, and they will be expressed if they are turned on. This 
allows scientists to identify traits they want to remove or to insert other traits found somewhere 
else in an organisms’ genome through the process of editing alleles out and replacing them with 
non-mutant alleles. Should we alter a human embryo if we are able to genetically test and 
confirm that it will be born with a lethal, degenerative disease, or should we allow the human 
race to populate naturally? Even in the case of using genetic engineering technology on already 
born humans, the question of what we are able to do versus what we should do still introduces an 
ethical debate, as altering the germline of an adult human changes the genetic makeup of not 
only the adult but also any offspring of that person.  
 For example, some genetic mutations that lead to the development of Alzheimer’s disease 
are known. If we are able to test for chromosomal content of human embryos, then we are able to 
detect if a human embryo will be born with a genetic disease. The first use of genetic engineering 
technology, specifically the CRISPR-Cas9 system, on human embryos was conducted in the 
                                                     
1 Lander, E. S. (2015). Brave New Genome. New England Journal of Medicine, 373(1), 5–8.
 https://doi.org/10.1056/NEJMp1506446. 
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summer of 2017 in order to fix a genetic disorder in a human embryo.2 Jennifer Doudna, a 
biologist from The University of California at Berkeley who co-discovered how to use CRISPR 
to edit genes, stated that “any scientist with molecular biology skills and knowledge of how to 
work with [embryos] is going to be able to [edit human embryos].”3 We are able to genetically 
engineer the germline in human embryos, which can be used to treat disease in future developing 
humans. The concern, however, is that of Edward Lanphier, the CEO of the California 
biotechnology company (Sangamo Biosciences) that is using the genetic engineering technology 
of zinc-finger nucleases to treat HIV in adults. Lanphier believes that there is no disease rationale 
for germline engineering, as it is “a slippery slope toward much more unacceptable uses.”4 
The consequences of genetically modifying an embryo are unknown. Currently, it is 
impossible for us to know if any unintended, genetic consequences will occur by genetically 
modifying the genome of a human embryo, and therefore it is impossible for us to know if the 
benefit outweighs the cost of this technology or treatment. “Any human embryo altered by 
CRISPR today would carry the risk that its genome had been changed in unexpected ways.”5 Not 
only this, but modifying the genetic makeup of an adult human, and specifically the germline of 
an adult human, can also introduce unintended, unknown detrimental consequences to not only 
the adult but also any of his/her children, and the human race. 
                                                     
2 Park, A. (2017, August 7). U.S. Scientists Use CRISPR to Fix Genetic Disease in Human Embryos for  
the First Time. Time Magazine. Retrieved from http://time.com/4882855/crispr-gene-editing- 
human-embryo/. 
 
3 Regalado, A. (2015). Engineering the Perfect Baby. MIT Technology Review. Retrieved from 
 https://www.technologyreview.com/s/535661/engineering-the-perfect-baby/. 
 
4 Regalado, A. (2015). Engineering the Perfect Baby. MIT Technology Review. Retrieved from 
 https://www.technologyreview.com/s/535661/engineering-the-perfect-baby/. 
 
5 Regalado, A. (2015). Engineering the Perfect Baby. MIT Technology Review. Retrieved from 
 https://www.technologyreview.com/s/535661/engineering-the-perfect-baby/. 
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There are multiple other ethical considerations that must be taken into account when 
considering the human application of genetic manipulation technology besides the unintended 
consequences and changing a germline. When using this technology as a human treatment, there 
are many religious aspects to take into account, as well as geographic, social, and financial 
aspects.  
In this thesis, I will attempt to determine whether or not it is ethically justifiable to use 
the CRISPR-Cas9 genetic engineering technology to edit the genetic makeup of a human 
embryo, and more specifically to modify the genetic makeup of the embryo’s germline. The 
reason for this focus is because at this time, the large majority of research has been directed 
towards germline modification rather than somatic cell modification in human embryos. This 
means that my analysis of the use of the CRISPR-Cas9 genetic engineering technology deals 
with germline modification, which affects all future generations from the embryo upon which 
CRISPR-Cas9 has been applied. In order to come to a conclusion to this argument, I will analyze 
the scientific background of the genetic engineering technology along with any other science that 
relates to its clinical use, the scientific benefits and risks of the technology, and the bioethical 
arguments for and against the use of the CRISPR-Cas9 system on human embryos. 
 
 
 
 
 
II. Scientific Background 
 10 
 
Introduction 
 A genome is an organism’s complete set of DNA, which includes all genes and 
hereditary material. Therefore, our genome (to an extent) determines who we are— it includes all 
any and all information necessary to build an organism. It determines what we look like (our 
phenotype), portions of our intelligence, and certain aspects of our personalities. Each gene in an 
organism is a specific sequence of DNA (our genotype), deoxyribonucleic acid, that codes for a 
certain sequence of RNA, ribonucleic acid, or a certain protein. DNA is structured as a double-
helix consisting of two complementary strands made up nucleotides, which contain a phosphate 
group, a sugar, and a nitrogenous base. There are four different nitrogenous bases in DNA: 
adenine (A), cytosine (C), guanine (G), and thymine (T), and RNA has the same four except that 
uracil (U) is substituted for thymine. In the complementary strands, adenine pairs with thymine 
and cytosine pairs with guanine. Each DNA sequence that codes for a gene is converted into a 
protein through two different processes that make up the central dogma of genetics. DNA is 
unwound and replicated, and then converted into RNA (which is single-stranded rather than 
double-stranded) through a process called transcription, and then the RNA is translated into the 
corresponding protein through a process called translation. These processes are continuously 
occurring in our bodies to maintain every one of our bodily functions.  
Genetic engineering has the ability to change our genome by manipulating our genes 
through biotechnology, which is technology that utilizes living organisms to develop a desired 
product. “Genome engineering technology offers unparalleled potential for modifying human 
and nonhuman genomes. In humans, it holds the promise of curing genetic disease.”6 These 
                                                     
6 Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., … Yamamoto, K. R.  
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genetic engineering techniques involve the precise modification of DNA through introducing 
mutations and allows for genes to be turned on or off. However, through altering our genetic 
makeup we have the ability to alter our germline, which is what we pass on to our future 
offspring, what our offspring pass on to their offspring, and so on. Our germline consists of germ 
cells that eventually produce sperm and eggs, and therefore contains all of the genetic 
information to be passed on.  
 
The CRISPR-Cas9 Genetic Engineering System 
One specific technology recently introduced to the scientific community is Clustered 
Regularly Interspaced Short Palindromic Repeats- associated protein-9 nuclease (CRISPR-
Cas9), which is used to introduce targeted mutations (insertions, deletions, and substitutions) into 
specific gene sequences.7, 8 A palindromic sequence of DNA or RNA is a sequence in which the 
sequence (reading from left to right, or 5’ to 3’) on the template strand matches the sequence 
(reading right to left, also 5’ to 3’) on the complementary strand. Repeats of sequences like these 
are involved in the CRISPR-Cas9 system. Insertions are genetic mutations in which a single base 
or group of bases are inserted into a genetic sequence, deletions are mutations in which a single 
base or group of bases are deleted from a genetic sequence, and a substitution is a mutation in 
which one base is substituted for another. The CRISPR-Cas9 system has many current 
                                                                                                                                                                           
(2015). A prudent path forward for genomic engineering and germline gene modification.  
Science, 348(6230), 36–38. https://doi.org/10.1126/science.aab1028. 
 
7 Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., … Huang, J. (2015). CRISPR/Cas9- 
mediated gene editing in human tripronuclear zygotes. Protein & Cell, 6(5), 363–372.  
https://doi.org/10.1007/s13238-015-0153-5. 
 
8 Peng, Y. (2016). The morality and ethics governing CRISPR–Cas9 patents in China. Nature  
Biotechnology, 34(6), 616–618. https://doi.org/10.1038/nbt.3590. 
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applications. Since the CRISPR-Cas9 system has the ability to target and induce mutations in 
one or two alleles, it can mimic heterozygous or homozygous knockout of a specific gene.9 
Therefore, this technology is essentially able to make certain genes inoperative, and in the case 
of gene therapy, it makes mutant, disease-causing alleles inoperative through gene editing. The 
CRISPR-Cas9 genetic engineering technology can correct genetic defects through introduction 
of new DNA sequences, change DNA sequences in pluripotent embryonic stem cells to culture 
certain specific differentiated tissues, and change germline DNA by altering the DNA in the 
nuclei of reproductive cells. Through modifying the genome of fertilized animal eggs and 
embryos, the CRISPR-Cas9 system has the ability to alter the genetic makeup of every 
differentiated cell in an organism, therefore confirming that the changes will be passed on to the 
offspring of the organism.10  
The CRISPR-Cas9 is a very new technology. CRISPRs were first investigated in the 
2000s and were later discovered in many bacteria and archaea. A few years later, in 2005, 
CRISPR was discovered to be derived from plasmid and viral origins, and it was found that 
CRISPR loci were transcribed. Combined with the observation that the Cas gene encodes 
proteins with nuclease and helicase domains, it was proposed that CRISPR-Cas could be a 
defense mechanism that had RNA memory signatures of past invasions. In 2007, the CRISPR-
Cas-mediated adaptive immunity was proved in Streptococcus thermophilus, and just a year later 
mature CRISPR RNAs (crRNAs) were illustrated to be guides in complexes with Cas proteins 
                                                     
9 Tu, Z., Yang, W., Yan, S., Guo, X., & Li, X.-J. (2015). CRISPR/Cas9: a powerful genetic engineering  
tool for establishing large animal models of neurodegenerative diseases. Molecular  
Neurodegeneration, 10(1). https://doi.org/10.1186/s13024-015-0031-x. 
 
10 Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., … Yamamoto, K. R.  
(2015). A prudent path forward for genomic engineering and germline gene modification.  
Science, 348(6230), 36–38. https://doi.org/10.1126/science.aab1028. 
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and the DNA-targeting activity of CRISPR was determined.11 
 The CRISPR-Cas9 system 
(see Figure 1)12 is derived from the 
bacteria Streptococcus pyogenes 
SF370, and uses specific RNA 
molecules within an RNA duplex 
(tracrRNA:crRNA) from this 
bacteria that have the ability to 
recognize human DNA sequences.13 
It is derived from type II CRISPR-
Cas systems in bacteria that provide 
bacteria with adaptive immunity to 
certain viruses and plasmids. The 
bacterial RNA is used as a guide that leads the endonuclease, the CRISPR-associated protein 
Cas9, to the targeted, matching location in the human genome in order to form base pairs. 14, 15 A 
nuclease is a type of enzyme (biological catalyst that can accelerate chemical reactions) that is 
                                                     
11 Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9.  
Science, 346(6213), 1258096–1258096. https://doi.org/10.1126/science.1258096. 
 
12 OriGene Technologies, Inc. (2018). CRISPR-Cas9, Gene Editing Tool. Retrieved from 
www.origene.com/products/gene-expression/crispr-cas9. 
 
13 Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., … Huang, J. (2015). CRISPR/Cas9- 
mediated gene editing in human tripronuclear zygotes. Protein & Cell, 6(5), 363–372.  
 https://doi.org/10.1007/s13238-015-0153-5. 
14 Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9.  
Science, 346(6213), 1258096–1258096. https://doi.org/10.1126/science.1258096. 
 
15 Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015). Don’t edit the human  
germ line. Nature, 519(7544), 410–411. https://doi.org/10.1038/519410a. 
 
Figure 1: Simple Diagram of the CRISPR-Cas9 System 
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able to cleave nucleic acids, the group of biological molecules that includes DNA and RNA. The 
CRISPR-Cas9 technology is simpler than others as it does not rely on the successful engineering 
of certain proteins that can bind to certain, specific engineering sequences, but rather just the 
correct pairing of RNA and DNA.16 Before CRISPR, it was not possible to precisely change the 
DNA of primates, and now we are able to do this easily and efficiently.17 
More specifically, the formation of base pairs with target DNA sequences that contain tri-
nucleotide protospacer adjacent motifs (PAM) allows the CRISPR-associated protein Cas9 to 
cleave the target DNA, introducing a site-specific double-strand break in the DNA. A double-
strand break in DNA is when both strands of a DNA duplex are cleaved, and if undesired are 
very detrimental and can be potentially lethal. The double-strand breaks in the target DNA 
(which is usually a sequence about twenty-three nucleotides long) are repaired by non-
homologous end-joining or homologous recombination directed repair. 18,19  
The specific, dual tracrRNA:crRNA was engineered in this technology as a single guide 
RNA (sgRNA), and it has two very necessary features for successful use of the technology: a 
specific sequence at the 5’ end of the RNA that determines the DNA target site in the organism 
and a duplex RNA structure at the 3’ end of the RNA that binds to the protein Cas9. Through 
                                                     
16 Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015). Don’t edit the human  
germ line. Nature, 519(7544), 410–411. https://doi.org/10.1038/519410a. 
 
17 Regalado, A. (2015). Engineering the Perfect Baby. MIT Technology Review. Retrieved from 
 https://www.technologyreview.com/s/535661/engineering-the-perfect-baby/. 
 
18 Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., … Huang, J. (2015). CRISPR/Cas9- 
mediated gene editing in human tripronuclear zygotes. Protein & Cell, 6(5), 363–372. 
https://doi.org/10.1007/s13238-015-0153-5. 
 
19 Tu, Z., Yang, W., Yan, S., Guo, X., & Li, X.-J. (2015). CRISPR/Cas9: a powerful genetic engineering  
tool for establishing large animal models of neurodegenerative diseases. Molecular 
Neurodegeneration, 10(1).  
 15 
these two features, the CRISPR-Cas9 technology can target any desired DNA sequence.20 Once 
the Cas9 protein is expressed, it forms a riboprotein complex with the sgRNA through 
interactions between what is called the scaffold domain of the sgRNA and positively-charged 
grooves of amino acids on the Cas9 protein that are exposed to the surface. The causes a 
conformational change of Cas9 into the active form that allows it to bind to DNA with the PAM, 
and the spacer sequence of the sgRNA is left free so it can also interact with the DNA.21 After 
association with the double-stranded DNA, Cas9 undergoes further conformational change, 
creating a channel between the two structural lobes of the Cas9 protein that can bind to the RNA-
DNA hybrid and to the stacked dual-RNA structure of the sgRNA. The hinge and bridge 
between these two structural lobes of Cas9, an arginine-rich α-helix, plays a central role in 
binding the sgRNA-target DNA hybrid.22 
 
 
 
 
Other Technologies Similar to the CRISPR-Cas9 System 
Along with the already observed success of modifying human embryos, the CRISPR-
Cas9 system has the benefit of being developed after older, less-successful technologies. The 
CRISPR system was developed to be a more precise and successful technology with potential 
                                                     
20 Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9.  
Science, 346(6213), 1258096–1258096. https://doi.org/10.1126/science.1258096. 
 
21 CRISPR/Cas9 guide. AddGene. https://www.addgene.org/crispr/guide/. 
 
22 Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9.  
Science, 346(6213), 1258096–1258096. https://doi.org/10.1126/science.1258096. 
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use on humans. Before CRISPR, there were (and still are) three other classes of engineering 
nucleases used for the purpose of gene editing: zinc finger nucleases, transcription activator-like 
nucleases (TALENs), and engineered meganucleases.23 The CRISPR-Cas9 system is the only 
one that utilizes a RNA-guided system, and it is, by far, the most specific of these gene-editing 
technologies. Compared to the other, similar genetic engineering technologies, CRISPR-Cas9 is 
much more advanced in the fact that is it the only one that has the ability to make extremely 
specific edits to the genome that could consist of just one base pair, and then repair the break 
after. 
 
Alzheimer’s Disease 
The CRISPR-Cas9 system has already been proposed for treatment for genetic disease 
and altering human embryos. In the case of certain genetic diseases in humans, more than 50,000 
genetic mutations that are linked to disease are caused by one base change, and most commonly 
that DNA change is from a G-C pair to T-A.24 
Alzheimer’s disease is one neurodegenerative disease in which the genetic components 
are known, and gene therapy is a viable option for Alzheimer’s alleviation. It is a brain disorder 
with symptoms of progressive dementia, loss of memory and thinking ability, and loss of ability 
to do some normal day-day actions (and it worsens over time).25 In Alzheimer’s disease, nerve 
                                                     
23 Meštrović, T., M.D.,PhD. (2016, January 13). How Does CRISPR Compare to Other Gene-Editing  
 Techniques? Retrieved from https://www.news-medical.net/life-sciences/How-Does-CRISPR-
 Compare-to-Other-Gene-Editing-Techniques.aspx. 
 
24 Belluz, J., & Irfan, U. (2017, October 25). Two new CRISPR tools overcome the scariest parts of gene  
 editing. Retrieved from https://www.vox.com/2017/10/25/16527370/crispr-gene-editing-harvard- 
mit-broad. 
 
25 McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical 
 diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the  
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cells deteriorate and therefore brain matter decreases (the cortex of the brain and the 
hippocampus are significantly reduced). About 5.5 million Americans currently have 
Alzheimer’s disease, and it is estimated that up to 16 million Americans will have this disease in 
the year 2050.26 There is no single cause of Alzheimer’s disease but rather it is a combination of 
several different gene mutations and related resultant problems. It is primarily caused by two 
factors: β-amyloid plaques and neurofibrillary tangles. β-amyloid plaques are largely caused by 
deposits of 39-43 amino acid-long β-amyloid peptide (which is from a larger β-amyloid 
precursor protein). Neurofibrillary tangles are aggregates of hyperphosphorylated tau protein.27  
The human tau gene is located on chromosome 17, and the tau protein (a phosphoprotein) 
stimulates tubulin assembly into microtubules in the brain— it is the major microtubule 
associated protein (MAP) of mature neurons.28 Tau is modified post-translationally, and the 
phosphorylation of tau negatively regulates its activity in the production of microtubule 
assembly. The hyperphosphorylation on tau protein its C-terminus end causes the aggregation of 
the protein, leading to the formation of neurofibrillary tangles. One possible target for 
neurofibrillary tangle alleviation is to genetically target GSK-3β (glycogen-synthase kinase-3β), 
a kinase that is involved in the pathogenesis of Alzheimer’s disease (a kinase is an enzyme that 
that chemically modifies other proteins by adding phosphate groups). The inhibition of GSK-3β 
                                                                                                                                                                           
auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease.  
Neurology, 34(7), 939–939. https://doi.org/10.1212/WNL.34.7.939. 
 
26 American Alzheimer's Association. (2018). Alzheimer's Association. https://www.alz.org/. 
 
27 Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., … Barrio, J. R.  
(2002).  Localization of Neurofibrillary Tangles and Beta-Amyloid Plaques in the Brains of 
Living Patients With Alzheimer Disease. The American Journal of Geriatric Psychiatry, 10(1), 
24–35. https://doi.org/10.1097/00019442-200201000-00004. 
 
28 Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related  
tauopathies. Current Alzheimer Research, 7(8), 656–664. 
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through genetic means has shown to reverse hyperphosphorylation of the tau protein in mice, and 
it is known that the human body tolerates inhibition of GSK-3β well.29 Targeting the mutated 
genes of tau kinases and tau proteins could lead to alleviation of neurofibrillary tangles in 
Alzheimer’s patients and therefore could alleviate symptoms of Alzheimer’s patients. The MAPT 
(microtubule associated protein tau) gene is the gene that encodes for tau proteins. Mutation of 
the MAPT gene results in the accumulation and hyperphosphorylation of tau proteins, and 
therefore genetically targeting the mutated form of this gene would reduce the instance of 
hyperphosphorylated tau.30 
The other major player of Alzheimer’s disease is accumulation of β-amyloid plaques. β-
amyloid plaques are a result of fragments of an amyloid precursor protein (APP) that harden in 
the brain and become insoluble (and therefore are unable to be eliminated).31 One of the main 
genetic factors in Alzheimer’s disease is apolipoprotein ε-4 (APOE-4), which is a precursor to 
the formation of β-amyloid plaques.32,33 Apolipoprotein E is involved with injury repair in the 
brain. It regulates lipid balance through the mediation of lipid transport into and out of the brain, 
                                                     
29 Gong, C.-X., & Iqbal, K. (2008). Hyperphosphorylation of Microtubule-Associated Protein Tau: A 
 Promising Therapeutic Target for Alzheimer Disease. Current Medicinal Chemistry, 15(23),  
2321–2328. https://doi.org/10.2174/092986708785909111. 
 
30 Iqbal, K., Liu, F., Gong, C.-X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related  
tauopathies. Current Alzheimer Research, 7(8), 656–664. 
 
31 Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., … Cole, G. (1996).  
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science  
(New York, N.Y.), 274(5284), 99–102. 
 
32 Gong, C.-X., & Iqbal, K. (2008). Hyperphosphorylation of Microtubule-Associated Protein Tau: A 
 Promising Therapeutic Target for Alzheimer Disease. Current Medicinal Chemistry, 15(23),  
2321–2328. https://doi.org/10.2174/092986708785909111. 
 
33 Dacks, P., PhD. (2016, November 16). What APOE Means for Your Health. Retrieved from  
 https://www.alzdiscovery.org/cognitive-vitality/blog/what-apoe-means-for-your-health. 
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which in turn helps with repair. There are three different isoforms of APOE, all of which bind to 
lipids, certain receptors, and β-amyloid proteins, but in different manners.34 It is specifically the 
ε-4 allele that increases likelihood of Alzheimer’s disease, and not the other two isoforms of 
APOE. “Currently, the best arguments [for human implementation of genetic engineering 
technology] might be for eliminating the ε4 variant at the APOE gene (which increases risk for 
Alzheimer's disease and cardiovascular disease).”35 
 
Conclusions 
The science behind both the CRISPR-Cas9 system and Alzheimer’s disease, when 
considered in conjunction, introduces a discussion of them being used together for medical 
benefit. Knowing certain genetic players in Alzheimer’s disease allows us to consider using the 
CRISPR-Cas9 system as possibly gene therapy to target the mutations that eventually lead to 
onset and progression of Alzheimer’s disease. The genetic component of Alzheimer’s disease is 
one that can be examined and easily tested for in human embryos, although it would be very 
difficult to genetically repair brain cells in developed, adult individuals. By genetically 
modifying embryos that have been tested to have the mutations leading to Alzheimer’s may, if 
successful, prove to be a viable therapy for those who would not have other viable options in life. 
There has been more than one human trial showing that the CRISPR-Cas9 system can be used in 
humans, and other trials are leading towards and testing human embryos. However, although 
possibly successful with further development, there are multiple other aspects of this treatment 
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that need to be brought into light in order to determine if this technology should ever actually be 
implemented in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. Scientific and Medical Benefits and Risks 
 
Introduction 
 Along with the many ethical concerns regarding the general field of genetic engineering 
and of the CRISPR-Cas9 technology itself that will be discussed later on in the thesis, there are 
also many benefits and risks from the scientific standpoint that must be considered. Whether or 
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not the scientific technology itself is safe enough to use on humans is especially important to 
consider before analyzing the ethical concerns human use— the CRISPR-Cas9 genetic 
engineering system must have minimal side effects and a very high accuracy rate in order to be 
considered acceptable to use on humans in a clinical setting. There have been other technologies 
similar to CRISPR which make CRISPR an impressive comparison. It is the only technology in 
this field that has introduced the option of clinically alleviating and curing human genetic 
diseases, especially those caused by a single base pair or just a couple base changes. The use of 
the CRISPR-Cas9 technology on humans would also allow further clinical research on inherited 
diseases in humans. However, there are also many off-target, unexpected risks of using CRISPR 
like unpredicted base changes, the creation of mosaic mutations, and double-stranded break 
errors. There have been multiple trials using CRISPR-Cas9 to edit non-human DNA, but most 
recently many that have edited human embryos, some viable and some non-viable. The results of 
each trial, as discussed below, are very similar yet also very different from one another in terms 
of the consequences and just how they were carried out experimentally. However, each trial also 
shows potential scientific benefits and risks of using the CRISPR-Cas9 system on human 
embryos.  
 
Genetic Engineering Trials: Benefits 
 The first attempt at genetically modifying a human embryo in the US occurred in summer 
of 2017 by a research team in Portland, Oregon at Oregon Health and Science University. This 
research team, led by Shoukhrat Mitalipov, used the CRISPR system to edit multiple one-cell 
human embryos. According to Mitalipov, the inherited defective genes were edited efficiently, 
and most importantly, edited safely. This means that there were no observed detrimental (and 
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unexpected) off-target effects in the embryos in the trial. After performing the trial, his team 
concluded that with CRISPR, it is possible to avoid off-target, unexpected effects. However, 
none of the embryos developed further than a few days, so the later possible side effects could 
not be examined.36 
 Not only was editing human embryos attempted in the United States, but it was also 
researched and attempted by researchers in China. The Chinese researchers at Sun Yat-sen 
University used CRISPR-Cas9 to alter mutant HBB gene that causes the β-thalassemia human 
disease. In each of their trials, non-viable human embryos were used. Although they were able to 
successfully edit out the mutant HBB gene in one of their trials, they reported multiple off-target 
effects and mosaicism, both which mean that some un-targeted DNA was edited.37 In both of the 
above cases, the germline of the human embryo was altered, whether the target gene was 
completely or only partially edited. 
 One reason Mitalipov’s group overcame the off-target effects and mosaicism was timing. 
Although possibly inapplicable to viable human embryos going through the in-vitro fertilization 
process, his group injected the CRISPR-Cas9 system into eggs at the same time they were 
fertilized with sperm (so at the moment of fertilization and zygote formation). He observed that 
compared to other technologies, it is possible to overcome the side effects for a truly beneficial 
outcome, even though the embryos in question were only observed for a few days. One of the 
largest risks of using the CRISPR-Cas9 technology to alter the human genome is the possible 
mosaic outcome, so the ability to overcome this issue is a large discovery in the field. However, 
                                                     
36 Connor, S. (2017). First Human Embryos Edited in U.S. MIT Technology Review. Retrieved  
from https://www.technologyreview.com/s/608350/first-human-embryos-edited-in- 
us/. 
 
37 Brown, H. (2015, April 26). World's First Genetically Modified Human Embryo Raises Ethical  
Concerns. http://theconversation.com/worlds-first-genetically-modified-human- 
embryo-raises-ethical-concerns-40766. 
 23 
as stated, the embryos were observed for only a few days so the possible mosaic phenotype may 
have not been observed (although seemingly not visible in the genotype). Mitalipov was also the 
scientist to introduce the world’s first cloned monkey, marking him as a leader in the field of 
genetics.38 
 Without the accidental, unpredicted consequences, the CRISPR-Cas9 technology would 
be beneficial in a clinical setting. The elimination of off-target affects would be one step closer 
to allowing the use of the CRISPR-Cas9 technology in a clinical setting, and therefore one step 
closer to the use of CRISPR-Cas9 for disease prevention, elimination, and alleviation. If 
clinically used on viable human embryos to go through in-vitro fertilization, it is possible that we 
could alleviate or even eliminate degenerative diseases that greatly affect the human population. 
With these recent discoveries in the CRISPR-Cas9 technology and the more general field of 
genetic engineering as a whole, it is necessary to further research the inherited diseases that 
CRISPR could be used for. This further research on inherited diseases could not only improve 
the outcome of genetically editing mutant genes, but also would improve the alleviation and 
curing of the diseases that are already present in adult humans. 
 As the specific base changes that cause many genetic diseases are known (see chapter 
two), scientist David Liu from Harvard developed the enzyme adenosine deaminase and attached 
it to the CRISPR-Cas9 system, which led to a very efficient process with very few off-target 
effects. In 28 percent of the cells tested by his research group, a mutation was successfully 
reversed with no unintended modifications. In the scientific rather than ethical sense, this 
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experiment leads CRISPR in a direction for efficient use in permanent modification of mutations 
for therapeutic reasons.39 
 
Genetic Engineering Trials: Risks 
 Although there are clear scientific benefits of using CRISPR and other genetic 
engineering technologies, there are many more scientific risks than benefits that may outweigh 
the benefits in the end. The unknown and known complications of the CRISPR-Cas9 system 
have led high-profile officials, like the US Intelligence agency, to label this gene editing 
technology a “weapon of mass destruction.”40 Officials are worried that it could be used to make 
viruses and plagues that can wipe out crops or severely alter human health. Although this could 
be a large threat to the human population, the US Intelligence Agency was also extremely 
worried about unregulated use of the technology, and how that would transfer over to heritable 
genes. For example, unregulated use of the CRISPR-Cas9 technology on humans could allow for 
the editing of physical traits in embryos. The more a certain physical trait was edited out and a 
different one edited in, there is a possibility of eliminating certain physical, hereditable traits. 
 Although CRISPR has been used to modify human embryos in successful trials, the 
unknown side complications like unpredicted base changes, mosaicism, and double-stranded 
breaks could mark CRISPR to be unsuccessful in its current state. The large possibility of off-
target effects means that there is a large possibility of unknown and unexpected detrimental and 
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maybe fatal complications, as the system could introduce other mutations that cause terrible 
illnesses and malfunctions. The trials that proved CRISPR successful in the modification of 
human embryos only observed the embryos for a few days prior to the experiment, which is not 
enough time to confirm that unexpected off-target effects would not take effect in the future of 
the embryo. There has not been a trial where a human embryo is viable to develop as a normal 
functioning human being (as it has not been approved yet), so the listed consequences are still 
unpredictable. 
 
Possible Unintentional Risks of the CRISPR-Cas9 System Explained 
 Unintended Base Changes 
 The CRISPR-Cas9 technology, as stated previously, can edit out unwanted target genes 
and replace them with the desired gene. However, when changing the bases of the genome, more 
than just the target gene may be edited. Just a single base insertion, where one base is entered 
into the base sequence, or a single base deletion, where one base is deleted from the base 
sequence, can cause translation errors that affect a large portion of the genome and possibly 
change the target gene to an unwanted product. This unpredicted translation error (the processes 
of transitioning RNA to proteins in the body) in the hereditable portion of the genome would 
cause permanent, possibly detrimental or even fatal consequences later in life. All edits made by 
the CRISPR-Cas9 system are permanent. It can also only be used where cells are actively 
dividing, as the Cas9 machinery is linked to cell division.41 The unintended, off-target gene edits 
caused by CRISPR is one of the largest and most scientifically and ethically concerning aspect of 
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the technology. For example, one CRISPR-Cas9 trial on viable embryos in China was attempting 
to correct the beta 41-42 mutation, which causes beta-thalassemia, but instead of fixing it another 
mutation was introduced instead.42 However, there has been one recent modification to CRISPR, 
where the Cas13 protein is used instead of Cas9, so that edits can be made to transient genetic 
material and the changes are reversible. An alteration of the CRISPR-Cas9 system similar to this 
would allow changes to be reversible, and any detrimental effects could be reversed if necessary. 
Therefore, it could fix certain genetic mutations without affecting the genome.43 
 Mosaicism 
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 Besides unintended base 
changes, another risk of the CRISPR 
gene editing technology is mosaicism. 
One Chinese research team at the Third 
Affiliated Hospital of Guangzhou 
Medical University carried out a 
CRISPR trial on viable human 
embryos with a heritable disease that 
were donated by patients of in-vitro fertilization, and actually had more success than their trials 
on non-viable human embryos. This research team was the same team that carried out the beta 
41-42 mutation trial in China. However, the largest consequence they encountered with the 
CRISPR technology was the creation of a mosaic embryo. In the cases of these embryos, the 
G6PD gene (which was the target gene), was completely turned off instead of edited. 
“[Mosaicism] would need to be solved before the methods could be used clinically to correct a 
disease” said Robin Lovell-Badge of the Francis Crick institute in London.44 Mosaic embryos 
are embryos that have a mixture of edited and non-edited cells (see Figure 2).45 With only partial 
editing of the embryo, it is still possible that the child would still grow up with the disease in 
question.46 This consequence occurs when the Cas9 mRNA is translated at a later developmental 
                                                     
44 Le Page, M. (2017, March 9). First Results of CRISPR Gene Editing of Normal Embryos Released.  
 Retrieved from https://www.newscientist.com/article/2123973-first-results-of-crispr-gene- 
editing-of-normal-embryos-released/. 
 
45 Memorial Şişli IVF & Genetics Center. Preimplantation Genetic Diagnosis by Next Generation  
Sequencing (NGS). Retrieved from http://www.tupbebek-genetik.com/en/genetics/next- 
generation-sequencing-ngs/. 
 
46 Le Page, M. (2017, March 15). Mosaic Problem Stands in the Way of Gene Editing Embryos.  
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stage than the sg RNA, so various different alleles result.47 One possible remedy for this problem 
would be to edit the eggs and sperm separately before fertilization, but that has not been 
attempted yet. Another hypothesis in the reduction of mosaic mutations is the promotion of 
degradation of the Cas9 protein. The prolonged expression of Cas9 in embryos could contribute 
to the creation of mosaic DNA mutations, so tagging Cas9 with ubiquitin in order to degrade it 
faster could reduce the mosaic mutations. It has been proven that tagging Cas9 with ubiquitin 
reduces its half-life and reduces the number of mosaic mutations. However, this has only been 
tested on monkeys and not human embryos.48 With mosaic mutations, “only about half the 
embryos will lead to live births, and of those that do, many could contain a mixture of cells with 
edited DNA and without,” according to Guoping Feng of MIT’s McGovern Institute for Brain 
Research.49  
 Double-Stranded Breaks 
 One last large complication of the CRISPR system is the induction of unwanted, extra 
double-stranded breaks. CRISPR induces a double-stranded break in order to edit the DNA. 
Normally the break is rejoined by non-homologous end joining or homology-directed repair 
mechanisms, but when an extra break is induced that was unintended it may not be repaired by 
the specific mechanisms. There also may be an issue that the intended double-stranded break is 
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never made at all. For example, studies have shown that a single mis-match in the sgRNA and 
target strands of DNA can prevent the Cas9-mediated cleavage. There are currently methods to 
predict off-target breaks when Cas9 is used in vivo, but not in vitro and the off-target effects 
could be very different between the two.50 The addition or removal of a double-stranded break in 
the DNA involved with the CRISPR-Cas9 system is not the only issue related to double-stranded 
breaks. Inaccurate repair of CRISPR-Cas9-induced DNA breaks could introduce other 
unintended mutations, although with the current technology this is very unlikely.51  
 Possible Risks of the CRISPR-Cas9 System: Conclusions 
 The possible complications of unintended base changes, mosaicism, and double-stranded 
breaks have the potential to create medical problems far greater than those that are needing to be 
fixed in the first place. For example, they could contribute to cell suicide (apoptosis) and the 
creation of cancer cells.52 
 The scientific benefits and risks of the current CRISPR-Cas9 technology are very 
contradictory as different trials have provided evidence for both the success and overcoming 
obstacles or the inability to. Each trial has its own caveat that makes the trials difficult to 
compare to each other. Whether or not viable or non-viable embryos were used, or how long 
each trial embryo was observed after and what they were testing, are all different variables that 
need to be taken into account when comparing the scientific benefits and risks of the CRISPR-
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Cas9 system for use in humans. The most important aspects are the effects on human embryos, 
especially those that are viable, and whether or not any unpredicted consequences are observed. 
Scientific Risks and Benefits: Alzheimer’s Disease  
 In reference to Alzheimer’s disease, there are risk genes and deterministic genes. The risk 
genes are those that increase the likelihood of inheriting the disease, and the deterministic genes 
directly cause the disease. There are variations in three certain genes that are inherited and will 
directly cause Alzheimer’s disease: the amyloid precursor protein, presenilin-1 and presenilin-2. 
Variations in presenilin-1 are the most common cause of early-onset Alzheimer’s disease. 
Although solely-inherited Alzheimer’s disease accounts for only 1% of Alzheimer’s cases, the 
inherited risk genes play a large role in all other cases as well. The risk gene with the largest 
known impact is apolipoprotein ε-4 (APOE-4).53 With the large genetic component of 
Alzheimer’s, the scientific advances to the CRISPR-Cas9 genetic engineering technology could 
eventually lead to alleviation of Alzheimer’s disease symptoms or complete eradication of the 
genetic mutations that cause the disease (and therefore elimination of the mutant disease genes 
from the germline). However, from a scientific standpoint, do the benefits outweigh the risks? 
 Using the data from the trials carried out with human embryos, the CRISPR-Cas9 
technology is not scientifically advanced enough to use on viable human embryos before in-vitro 
fertilization. Although some trials have discussed and tested methods to reduce or eliminate the 
complications of off-target effects and mosaic mutations, they have not been 100% effective, and 
for use on unborn humans, there needs to be a much larger success rate than was shown (as little 
as one to three embryos per trial were successful without visible off-target effects). Even though 
genetic engineering on the human germline has progressed further than anyone thought or 
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imagined it would, it still is not in the stage to be used on humans. Especially with the possible 
off-target base changes and creation of mosaic mutations, any introduction of a mutation that 
would cause the embryo in question to grow up and not live a normal, healthy life (even with the 
original target disease edited out) may not be worth the risk (especially if we do not know what 
that off-target mutation may do).  
Conclusions 
With more research on the technology, the reduction of these unpredicted, unwanted off-
target effects, whether it be base changes, mosaic mutations, or double-stranded break errors, 
would be reduced. However, there does still need to be an improvement scientifically in the 
technology before it can really be used to alleviate or eradicate any human, genetic disease in 
human embryos that will later grow up and live a normal life.  
Biologist Guoping Feng of MIT’s McGovern Institute for Brain Research said in 2015 
that he “thinks actual gene-edited humans are ‘10 to 20 years away.’”54 Feng also explained that 
at the time, making specific edits with CRISPR, like editing or swapping DNA bases, works only 
about 20% of the time.55 Although a couple of years have passed since this statement and the 
technology has improved, the percentage is still not where it needs to be for the scientific 
benefits of using the CRISPR-Cas9 technology on humans to outweigh the risks. One thought of 
scientists in the field is to combine the CRISPR-Cas9 technology with the current research in 
stem cells in order to generate a higher success rate. With the stem cells, scientists can edit genes 
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in stem cells before turning them into an egg or sperm for fertilization.56 Although this has not 
been done yet, it would help bring the gene editing technology a step closer for human use. With 
further research and improvement, however, the scientific and medical benefits could outweigh 
the risks of using the CRISPR-Cas9 technology on human embryos. 
IV. Analyzing the Ethical Considerations of Genetic Engineering 
 
Chapter Introduction 
In this section of the thesis, I am going to analyze the ethical arguments for and against 
the use of the CRISPR-Cas9 technology on human embryos in order to eliminate or alleviate 
Alzheimer’s disease. In order to accomplish this, I will present two case studies that relate to the 
use of the CRISPR-Cas9 engineering technology on human embryos and apply the two major 
theories of bioethics, deontological theory and consequentialist theory, the four major principles 
of medical ethics, respect for patient autonomy, beneficence, non-maleficence, and justice, and 
the current religious and public views to each case. 
 
Medical Ethics Background 
The field of medical ethics applies to all clinical medicine practices and clinically-related 
scientific research. There are four principles to be considered in discussing the field of medical 
ethics: respect for patient autonomy, beneficence, non-maleficence, and justice. When 
considering medical ethics in terms of genetic engineering, and especially in terms of altering a 
human embryo, many of these theories and principles may be violated. 
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Two Theories of Bioethics Background 
It is imperative to understand the major theories of bioethics along with the four 
principles of medical ethics in order to analyze the ethical question at hand. There are two 
theories of bioethics: deontology and consequentialism. The theory of deontology was 
formulated by Immanuel Kant and follows rules based ethics. This theory states that we must not 
violate rules which depend on rational thought, and we must not intentionally harm someone 
else. In order to decide whether something is ethically justifiable or not, one must be capable of 
rational thought. In this theory, there are certain obligations and commitments that we cannot 
violate, regardless of the outcome (i.e. even if the outcome is ideal), and we cannot use other 
humans for the purpose of achieving our goals. One of the largest aspects of deontology is that 
we cannot lie. Kant also states, as a part of deontological theory, that no person can be simply 
used to fulfill one’s own goals, and we cannot intentionally harm. 
 The consequentialist theory, formulated by Jeremy Bentham and John Stuart Mill, is 
quite similar to an economic theory. This theory focuses on the outcomes of behavior, and is 
therefore commonly contrasted to deontological theory. It judges whether something is ethically 
justifiable or not based on what a behavior produces and not the path it took to get to that 
outcome. According to consequentialism, we are trying to achieve the greatest good for the 
greatest number of people, which is similar to a cost-benefit analysis. Contrary to deontology, 
consequentialists will sacrifice individuals to save the many and achieve personal goals. 
 
Case Study 1: Introduction 
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In this section, I am answering the following question: Is it ethically justifiable to use the 
CRISPR-Cas9 technology, in its current condition, to eliminate risk or determinate genes of 
Alzheimer’s disease? In order to answer this question, I propose the following scenario: 
 A middle-aged couple had been attempting to conceive a child and they just found out 
that the woman is pregnant. They have both been screened for their genetic makeup, and the 
father is positive for the mutated apolipoprotein ε-4 (APOE-4) gene that is the major precursor 
for the formation of β-amyloid plaques, and therefore a large precursor for Alzheimer’s disease. 
Worried about the possible inheritance of this gene, the couple decides to screen their embryo for 
the APOE-4 gene. They have the belief that they should do anything and everything to make sure 
that their child has the best and longest life possible. After screening, it is determined that the 
embryo also carries the mutated APOE-4 gene that is a precursor for Alzheimer’s. They decide 
that they want to use current genetic engineering technology, the CRISPR-Cas9 system, in order 
to edit out the mutated gene and replace it with a normal one. However, the couple’s physician is 
skeptical about using the technology in its current state to perform this procedure. Is it ethically 
justifiable for the couple and the physician to do go ahead with the editing of the embryo? My 
conclusion, as shown in the arguments below, is that at the current state of the CRISPR-Cas9 
technology, it is not ethically justifiable for the couple to edit out the mutated APOE-4 gene from 
their growing embryo. 
 
Case Study 1: Analyzing Deontological Theory 
 Editing the mutated gene out of the couple’s embryo would violate major aspects of 
deontological theory. First of all, it can be argued that the couple is not currently relying on 
rational thought. Although it could be argued that wanting to do everything for your child is 
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rational, in this case the parents are not scientists that know the small details of the unintended 
consequences, even if they have been informed of these consequences by their physician. They 
are trying to do everything possible to help their child, and even though editing out the mutated 
gene is possible, it is not rationally okay to do in its current state. As stated in the previous 
section, the scientific issues of unintended base changes and mosaicism could lead to 
consequences we have not yet discovered or predicted. Even though the couple wants to use it to 
possibly eliminate the risk of Alzheimer’s or alleviate later symptoms of Alzheimer’s in their 
future child, they are not considering the possible side effects. Although Alzheimer’s could be 
gone, many other complications, which possibly could be fatal, could arise from the use of the 
CRISPR-Cas9 system. 
 From the physician and scientist standpoint, the physician would be violating 
deontological theory as he would be using someone else in order to reach his own goal of 
eliminating and/or alleviating Alzheimer’s disease, especially knowing that there could be 
possible consequences. Deontological theory states that we cannot use others to achieve personal 
goals. He has the obligation to give the best possible care to each patient he encounters, and to 
make sure that he helps the patient become as healthy as possible. Knowing that there are 
possible detrimental consequences of using the CRISPR-Cas9 technology in its current state 
would be violating the commitment he made when he became a physician. 
Kant places a lot of emphasis on the importance of the rational person, and how humans 
must be considered rational in order to make the decision of what is right and wrong. Around the 
age of 12-15, Kant allows children moral status because they are then capable of rational 
thought. According to this theory, embryos are not capable of rational thought and do not have 
moral standing. However, the embryos will eventually develop into infants and later adults with 
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a moral standing. Kant would originally discount the moral standing of embryos, but they do 
have potential to eventually develop rational thought, which must be considered in the 
deontological analysis of each of the following case studies. In the real world, deontological 
theory would not apply to these embryos that we are able to genetically manipulate until they are 
capable of rational thought. 
Kant also states, as a part of deontological theory, that no person can be simply used to 
fulfill one’s own goals. This applies in the sense that embryos cannot give consent at the time 
they would be edited, and when they reach the point of rational thought we have already violated 
the prohibition against using them for our own personal goals without their permission and 
consent. 
 
Case Study 1: Analyzing Consequentialist Theory 
 Not only through the theory of deontology, but also through the consequentialist theory, 
the gene editing of this embryo would not be ethically justifiable. In this theory, we are trying to 
act in a way where the outcome produces the greatest good for the greatest number. In the 
scenario described above, the physician would be editing a gene that is in the embryo’s germline, 
which means that the edited would be passed on to future generations. Since the CRISPR-Cas9 
technology is not at the current state of a 100% success rate, or even a very high success rate, he 
could be causing more harm to the masses than good, which would violate this aspect of 
consequentialism. Through a cost-benefit analysis (as this theory is similar to economic 
theories), the risk of harm resulting from performing this procedure in this scenario greatly 
outweighs the benefits, as the unpredicted consequences could end up to be more fatal than 
Alzheimer’s.  
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 Unlike the theory of deontology, however, the consequentialist theory allows for sacrifice 
of the individual to save the many (i.e. one is able to use others to accomplish personal goals). 
Following this principle, it would be okay to try to edit the germline of this embryo in order to 
observe the outcome. Even if the outcome were detrimental rather than successful, it would still 
provide new research and new observations on what may happen when altering a human embryo, 
and therefore could help the masses in the future. However, this still would violate the other 
concepts of consequentialist theory. 
 Going along with the same concept of providing the greatest good for the greatest 
number, it could also be argued the opposite way, that it would not be providing good for the 
greatest number. Using CRISPR-Cas9, with its known complications, could easily cause more 
harm than good, as stated above, especially in the discussion of editing the germline and not just 
somatic cells. In this sense, using the technology and harming the human embryo would not 
provide the greatest good to the greatest number as it would not only harm the human embryo 
but also emotionally harm the parents and others involved in the procedure, as well as harm all of 
the future offspring of the embryo. 
 
Case Study 1: Analyzing Non-Maleficence 
 The physician, in this case, is also clearly violating the medical ethics principle of non-
maleficence. This principle requires that we do not intentionally harm any patient, whether it be 
from performing an act or not performing one at all.57 We currently do not have confirmed 
knowledge that using the CRISPR-Cas9 system will not introduce harmful consequences, but we 
do know that it will introduce consequences as mosaicism and unintended base changes. With 
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this knowledge, although we also do not know exactly what the unintended consequences may 
lead to in the future, the physician could not perform this gene editing procedure while also 
following the principle of nonmaleficence. 
 
Case Study 1: Analyzing Beneficence 
Similar to violating the concept of producing the greatest good for the greatest number, 
editing out the mutant Alzheimer’s gene in this embryo would violate the medical ethics 
principle of beneficence. Beneficence states that physicians have the duty to take steps towards 
removing harm from any patient and to always be of benefit to the patient.58 Since CRISPR, in 
its current state, does not have a high success rate (i.e., a low rate of unintended consequences), 
the physician would not be fulfilling his duty of intentionally providing benefit and taking 
positive steps to help the patient, and in this case, the human embryo. On the contrary, in 
knowing all of the possible consequences, the physician would really be harming the patient. The 
principle of beneficence includes preventing harm and doing good along with removing harm. In 
this scenario, the physician would not be preventing harm as he, again, does not know what the 
possible consequences are. Although not removing the mutant gene would allow the human 
embryo to grow into someone who develops Alzheimer’s disease, the unexpected consequences 
of the CRISPR-Cas9 system may cause other, more harmful consequences, and therefore 
performing the procedure would not be preventing harm but rather causing harm. Lastly, 
although it may seem as if the physician is doing good in this scenario by preventing or 
alleviating Alzheimer’s disease in the viable human embryo, once again the unintended 
consequences like unexpected base changes and mosaicism may end up being worse or more 
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quickly fatal, in which case the physician would not be doing good to the patient or the patient’s 
family. 
 
Case Study 1: Analyzing Religious Views 
 From a religious perspective, the physician could also be construed as “playing God” in 
this scenario. By choosing whether or not to carry out the gene editing process, he is essentially 
choosing when and how the child may live and die. He is deciding whether or not the child could 
develop Alzheimer’s disease or not, and he knows that there are possible, unpredicted 
detrimental outcomes if he chooses to go ahead with the procedure. In this case he is violating 
some essential rules of being a human bring from a religious perspective because he as a person 
may not be in the position to decide whether to do right or wrong because he is not God. 
 
Case Study 1: Conclusions 
 In applying deontological and consequentialist theories and the principles of 
nonmaleficience and beneficence, and in considering some oppositional religious views, it can be 
concluded that with the CRISPR-Cas9 in its current technological state, it would be unethical to 
edit the mutant gene out of the viable human embryo in question. Even “the American Medical 
Association, holds that germ-line engineering shouldn’t be done ‘at this time’ because it ‘affects 
the welfare of future generations’ and could cause ‘unpredictable and irreversible results.’”59 It 
violates major aspects of both the deontological theory and the consequentialist theory of 
bioethics and therefore it cannot be concluded that it is ethically justifiable to use the CRISPR-
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Cas9 system to edit out the APOE-4 gene that is a precursor for Alzheimer’s disease in the 
human embryo. 
 The main basis of concluding that is it not ethically justifiable to edit the mutant gene out 
of the visible human embryo in question is the fact that the CRISPR-Cas9 system is not in a 
scientifically current acceptable state for use on humans, and still has many problems to 
overcome.  
 
 
Case Study 2: Introduction 
What if the CRISPR-Cas9 genetic engineering technology was acceptable for use in 
humans (in that the unintended consequences were completely avoided), and rarely ever made 
mistakes? Would it be ethically justifiable to use the CRISPR-Cas9 system, when it is at the 
point of an extremely low off-target effect rate, to eliminate risk or determinate genes of 
Alzheimer’s disease? In order to answer this question, I propose the following scenario: 
 We project ourselves into a future in which multiple studies and trials with the CRISPR-
Cas9 system have been performed, and the off-target effects like mosaicism, unpredicted base 
changes, etc. (the problems explained in the previous chapter) have been reduced to a 1% 
occurrence rate. The CRISPR-Cas9 system has recently been implemented in a small number of 
premier hospitals and research centers around the world, with only few in America (in large 
metropolitan cities as Houston, New York City, and Boston), in order to edit mutant and possibly 
fatal genes in genetically screened human embryos. At this point in time, the CRISPR-Cas9 
system is only being used in a clinical setting to edit mutant genes that are the sources of genetic 
diseases that are eventually fatal or cause an extremely painful and poor quality of life. The price 
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to screen your fertilized embryo for the diseases that are being edited by CRISPR-Cas9, attend a 
diagnostic appointment with a physician and scientist who will perform the procedure, and have 
the procedure done with follow up appointments is extremely expensive (although the price to 
perform the procedure with CRISPR-Cas9 is actually very low), and only very little if any of 
these costs are covered by private insurance (none of the process covered by Medicare of 
Medicaid, or any government subsidized public insurance). “An in-vitro fertilization procedure 
costs about $20,000 in the United States. Add genetic testing and egg donation or a surrogate 
mother, and the price soars to $100,000,” and that is without the use of CRISPR-Cas9 to actually 
edit out the gene.60  
 A young wealthy, upper-class couple from a small town in the mid-west has one middle-
school aged daughter who learned the basics of genes and DNA in her science class and asked 
her parents if she could be genetically screened, as one of her classmates had been and shared 
about it in her class. Her parents agreed and decided to also get screened. Once their results came 
back, both the mother and the daughter realized that they were positive for the mutated APOE-4 
gene that is the major precursor for the formation of β-amyloid plaques, and therefore a large 
precursor for Alzheimer’s disease. Although the daughter did not know what that meant, the 
mother, who had to undergo in-vitro fertilization to have her daughter, was very worried about 
her daughter and her next child (as she and her husband were planning to have at least one other 
child). 
 Once the couple, who had a very good private insurance plan, was ready to have their 
next child, again via in-vitro fertilization, they decided to screen the fertilized embryo for the 
mutated APOE-4 gene. The results showed that the embryo they were planning to implant was 
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positive for the mutated APOE-4 gene. The couple decided to schedule an initial appointment 
with the physician and scientist who could perform the CRISPR-Cas9 procedure at the nearest 
hospital to them, which was a two-hour flight away. The physician and scientist jointly decided 
that the couple was a good candidate to undergo CRISPR-Cas9 editing to edit the mutated 
APOE-4 gene out of their embryo. Although insurance did not cover the procedure, the couple 
had enough money to go forward with the process. 
 Even though, at this hypothetical point in time, the CRISPR-Cas9 technology is 
scientifically sound and makes very minimal, if any, errors, is it ethically justifiable for the 
couple, physician, and scientist to go through with the procedure? My conclusion, as shown in 
the arguments below, is that even with an almost-perfected CRISPR-Cas9 technology (almost-
perfected as there are always risks of any clinical procedure), in considering the principle of 
justice in the distribution of scarce resources, it is still not ethically justifiable for the couple to 
edit out the mutated APOE-4 gene from their growing embryo until the technology is much more 
accessible around the world. 
 
 
Case Study 2: Analyzing Justice 
 Performing the clinical procedure of editing out the mutant genes with the CRISPR-Cas9 
system violates the principle of justice. This principle requires the fair distribution of goods in 
the healthcare system, and that equal people should be able to receive equal treatment.61 
According to the principle of distributive justice, the criteria for the just allocation of scarce 
medical resources includes the following: “to each, an equal share; to each, according to need; to 
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each, according to effort; to each, according to contribution; to each, according to merit; and to 
each, according to the ability to pay.”62 
 In this scenario, which is a very likely case once the technology is at the point where it 
can successfully and accurately perform this procedure, the couple is very wealthy and has the 
ability to travel across the country in order to meet with the doctors that can perform the 
procedure, and they have the ability to pay for the whole process out of pocket (rather than it 
being covered by insurance). For any kind of medical procedure of the like, only the very few 
who can afford the travel and the cost of the medical portion itself are able to go through with 
this process. The accessibility is also very limited, as it is, in this scenario, only performed at 
very few hospitals around the world. Is this fair to those with the same problem, but not the same 
financial stability? “What if these improvements were only available to the richest societies, or 
the richest people?”63 There must be some fairness in the distribution of technology and scarce 
resources like the CRISPR-Cas9 gene editing system.  
 From a financial aspect, the fairness of medical treatment is a large issue in our current 
society and in this specific scenario. It can be argued that it would not be ethically justifiable to 
perform this procedure on this specific family because this family is only one of the extreme few 
who could follow through with it, and then the only embryos that would have the disease edited 
out would be those of wealthy upper-class families. Since this clinical procedure is not covered 
by insurance, it would be extremely expensive. Therefore, a new gap between rich and poor 
would be created. In this case, Alzheimer’s disease would eventually shift to only be present in 
those families who were not as financially stable, as the general cost of the treatment is 
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extremely expensive. In order to remedy this issue with distributive justice, a much more 
expansive financial plan needs to be implemented. Whether the treatment is covered only partly 
or fully, it would need to be covered by both private and public insurance policies. If not covered 
by insurance, the price would need to be reduced or an association be created that would finance 
the procedure for those who do not have the funds to pay for it at the more expensive price. 
Without fixing the financial instability and cost, there would be no distributive justice in a 
financial aspect, and the gap created would render the technology ethically un-justifiable. 
Another reason the procedure is only accessible in few hospitals and few countries is due 
to the views of genetic engineering. For example, in a study conducted in the United Kingdom, 
“the public’s ethical concerns [regarding genetic engineering] are associated with applications 
involving the use of animals or of human genetic material,” and a large portion of those concerns 
are based on the “’unnaturalness’” of altering animal and human genetic material.64 In “western 
Europe, 15 of 22 nations prohibit the modification of the germ line. Although the United States 
has not officially prohibited germline modification, the US National Institutes of Health’s 
Recombinant DNA Advisory Committee explicitly states that it ‘will not at present entertain 
proposals for germ line alterations.’”65 Although using the CRISPR-Cas9 technology in some of 
these areas may not be banned or illegal, in countries that have an extreme negative attitude 
towards using the technology on human genetic material, the procedure may not be accessible. 
Also, “in China, an invention that contravenes social moral principle cannot be granted patent 
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right.”66 If it is not available in certain countries or areas like this, people may have to travel 
further and therefore spend much more money solely on travel and lodging expenses, which 
would polarize the distribution of the CRISPR-Cas9 resources even more (to where it is available 
to a much smaller, wealthier group of people only). This would further violate the medical ethics 
principle of justice. 
 From a healthcare perspective, the distribution of this resource would also be extremely 
unfair and unequal. This procedure would have to be in effect with little risk for a long period of 
time before it would be largely or fully covered by private healthcare companies, and even much 
longer for public or government subsidized healthcare policies. Therefore, even if it were 
partially covered by healthcare, only those with very good, private healthcare plans would be 
able to afford the procedure. Therefore, only the wealthy who are able to pay for the more 
expensive and higher-coverage healthcare plans would be truly able to pay, so the only people 
able that would have the procedure covered by their healthcare plan would be those who could 
probably afford to pay for it out-of-pocket in the first place. It would only further the two-class 
system of healthcare. The coverage of this procedure by all healthcare plans is very, very far into 
the future (if it would even happen at all), especially with how new the technology is, even after 
more years of research to when the technology makes very little to no off-target, unpredicted 
changes. There would be no distributive justice under these circumstances. 
 
Case Study 2: Analyzing Deontological Theory 
 From a deontological perspective, editing the mutated APOE-4 gene out of the couple’s 
new, in-vitro, viable embryo would still not be ethically justifiable. One main statement of 
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deontological theory is that we must not violate rules, and there are certain obligations and 
commitments we cannot violate, regardless of outcome. Two of the rules is that we may not use 
others to achieve personal goals, and that one must be of moral standing and have rational 
thought to make decisions (especially those of right or wrong). In this case, the argument is the 
same as in the first case study. The embryo is not able to make its own decisions, as it does not 
yet have moral standing and cannot make rational thoughts. Although it will develop into a 
human who can, at the moment it cannot, so the parents would be making their decision based on 
what they think is best. This would be fulfilling their goals through using the child. 
The CRISPR-Cas9 system “is likely to power a new generation of gene treatments for 
serious diseases,” but is that it?67 One of the main concerns of the public (whether CRISPR-Cas9 
is scientifically accurate or not) is that the CRISPR-Cas9 technology will be used for editing that 
goes much further than editing out mutant genes that cause terrible diseases, for example, using 
it to create “a dystopia of super-people and designer babies for those who can afford it,” and 
down a further slippery slope in which “’most of the public does not appreciate.’”68 The main 
fear is that “if germ-line engineering becomes part of medical practice, it could lead to 
transformative changes in human well-being, with consequences to people’s life-span, identity, 
and economic output.”69 The negative views of CRISPR-Cas9 seem to be becoming even more 
negative as the thoughts of “designer babies” and “editing the human race” have been coming 
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into light. 
 Although the CRISPR-Cas9 system is being analyzed in order to eliminate or alleviate 
disease, specifically Alzheimer’s disease, would even just that lead to an era of human 
augmentation and enhancement? For example, people with a specific variant of the Amyloid 
precursor protein are protected against Alzheimer’s and dementia, so they remain very sharp in 
old age compared to those who do not have the variant. Using CRISPR-Cas9 to introduce that 
variant into someone could be construed as enhancing that human rather than just protecting him 
or her from a harmful disease.70 The use of this technology to make people just a bit sharper, 
smarter, more athletic, more disease-resistant, etc. would be bordering, if not crossing the line of 
what is considered an acceptable use of this technology. However, humans with rational thought 
did create this technology, so its use, in any scenario, could be argued to be rational, even though 
that argument does not outweigh the argument against using CRISPR-Cas9 for anything but 
disease prevention. 
 
Case Study 2: Analyzing Consequentialist Theory 
Consequentialist theory can be used to argue both for and against the ethical justifiability 
of use of CRISPER-Cas9. From one standpoint of a consequentialist theorist, using the CRISPR-
Cas9 technology to edit out the mutant APOE-4 gene in this scenario (where the technology is 
scientifically sound and extremely accurate), is not ethically justifiable. The consequentialist 
theory requires that we act in a way where the outcome produces the greatest good for the 
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greatest number of people. Using this technology would create the greatest good for the greatest 
number by editing out the mutant APOE-4 gene, but if the technology went any further than this 
it could have the ability to eliminate a certain population of certain gene pool which would do 
the opposite of what consequentialist theory calls to do. Eliminating a certain gene pool or 
certain physical aspects would lead to less diversity and variety around the world, which would 
not be providing the greatest good for the greatest number. 
From another standpoint of a consequentialist theorist, using the CRISPR-Cas9 
technology to edit out the mutant APOE-4 gene in this scenario is ethically justifiable. As stated 
above, the consequentialist theory calls to act in a way where the outcome produces the greatest 
good for the greatest number of people, regardless of the steps it took to get to the outcome. In 
any case where the germ-line, and therefore what will be passed on to later generations, is edited, 
any gene editing technology must be questioned.  
However, in this scenario, eliminating or even just alleviating Alzheimer’s disease in this 
one embryo would produce greater good than harm for the greatest number of people, as the 
parents are happy and the viable embryo will have a less extreme case of Alzheimer’s disease or 
not develop Alzheimer’s disease at all (and will also affect later generations). Also, through the 
argument of possibly making enhanced humans, whether it be with greater intelligence or a 
different trait (even though it is still not completely clear how genetics affect individual 
intelligence), this technology could cause further developments and innovations that could 
change the world for the better by increasing problem-solving and entrepreneurial skills.71 
Although not the same as in the last chapter, this could still bring about very different unintended 
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consequences for the human race, as certain children would be more intelligent or superior in 
some other way due to the ability of the parents to afford the procedure. But this begs the 
question, are we in a post-ethics technological world? Through analyzing the current views and 
arguments on the CRISPR-Cas9 technology, I personally do not yet think we are because the 
topic of editing humans, and many other topics similar, are still highly debated and thought of 
negatively. However, we could be on the path towards one. 
 
Case Study 2: Analyzing Religion 
From a religious standpoint, performing this procedure may be construed as human 
beings “playing God,” and therefore violating the rules of human life. Certain areas of the world 
have different religious-based opinions on this technology. For example, “life science research in 
China does not encounter the same religious objections compared with the West and research 
based on CRISPR–Cas9 technology, such as using such gene-editing technology in human 3PN 
zygotes, does not provoke the same level of controversy.”72 The Christian Research Institute, in 
contrast, states that  
“Christians must focus on questions of disease versus enhancement, the 
purpose(s) of medicine, and the dangers involved in possibly releasing new (and 
unintended) harmful genes into the human gene pool. The primary purpose of 
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medicine ought to be, in Nigel Cameron’s words, ‘a tradition of healing.’”73  
The Christian Research Institute also explains that through the analysis of Christian 
Doctrine, “We lack both the wisdom and purity necessary to decide matters of human 
‘perfection.’ It is, therefore, immoral to use such genetic technologies as human eugenics.”74 
These statements and arguments are discussed due to the ability to pick and choose genes to be 
edited before a human is even born, which is also one of the many reasons why gene editing was 
added to the threat list as a possible “weapon of mass destruction and proliferation” by the US 
intelligence community in 2016.75 
 
Case Study 2: Conclusions 
 Using the CRISPR-Cas9 engineering technology to solely edit out detrimental, mutant 
disease genes, like the mutant genes that cause Alzheimer’s disease, is ethically justifiable when 
the technology is in a state of almost perfect accuracy. However, there are still major problems 
relating to justice, as well as violations of deontological and consequentialist theory in the 
analysis of this case study. Not only this, but there are also large fears of other use of the 
technologically (creating a slippery slope) that would not render it ethically justifiable even if it 
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is in a state of perfect accuracy, as it could also affect the human race and evolution through 
other, more physically apparent edits.  
 
 
 
Chapter 4 Conclusions 
From the two case studies discussed above, it can be concluded that it is not ethically 
justifiable to use CRISPR to edit the germline of a human embryo. The violations of the most of 
the principles of medical ethics (the first case study relates to beneficence and nonmaleficence, 
and the second relates to justice), as well as of deontological and consequentialist theories, 
greatly outweigh the ethical benefits of using the technology on human embryos, whether it be in 
the technology’s current state or in a state where detrimental side effects have been eliminated 
and it is at an almost-perfect accuracy. 
Although I concluded that the CRISPR-Cas9 gene editing technology is not ethically 
justifiable for use in either scenario, a hard set of limits of where application of this technology is 
ethically justifiable could be introduced that would make the public have a more positive view of 
not only the CRISPR-Cas9 technology but also any other genetic engineering technology for use 
on humans.  
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V. Proposed Limitations of the CRISPR-Cas9 System 
 
“Scientists are developing ways to edit the DNA of tomorrow’s children. Should they stop 
before it’s too late?”76 
 
The limits that need to be set on the CRISPR-Cas9 technology, when used to modify the 
germline of human subjects, range across all aspects of the ethical arguments outlined above. 
Although we currently are not in an age where this technology is openly and widely used on 
humans, the limitations for future use need to be addressed as the technology is coming closer 
and closer to human use every day. The main limitation, and the most concerning to the general 
public, would address how far we should be allowed to take this technology and what exactly we 
should use the technology for. 
 The use of genetic engineering, and especially the CRISPR-Cas9 system, on humans 
could be used for much more than editing out and replacing one specific gene. If we were to 
develop the technology to an almost perfect accuracy, using it to edit out and replace genes that 
would cause detrimental and possibly fatal diseases would be the best possible outcome. 
However, once the technology gets that far it could and may also be used to many other 
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procedures. For example, if we were able to edit out a gene causing Alzheimer’s disease and 
replace it with a non-mutated gene, we could also edit out a gene for a certain physical trait and 
replace it with a different physical trait. “’There are moral and ethical issues, but one of the 
profound questions is just the appreciation that if germ-line editing is conducted in humans, that 
is changing human evolution.’”77 Although most physical traits like hair color, skin color, eye 
color, etc. are determined by the combination of multiple genes, even changing one of those 
genes could very likely lead to the embryo being born with the desired trait or a trait much more 
similar to the desired trait than the original. The genetic determination of other human traits, like 
athleticism and intelligence, is not fully known for humans, although it is known that genetics 
play some role for both of them and other traits of the like. There is constant research on these 
traits and their genetic components, so with more research in the time it would take to perfect the 
CRISPR-Cas9 technology, editing genes in human embryos to make the child smarter or more 
intelligent could be a realistic possibility. These thoughts culminate into the main fear of the 
public: using this technology to have superior children, or “designer babies.”78 
 Playing into this fear would also be the financial aspect of using genetic engineering to 
alter the genetic makeup of unborn children. Using the technology on humans would be very 
expensive, and as described above not fully covered by insurance, so only the wealthiest would 
be able to use it. Therefore, the wealthiest people would be able to create superior children, 
which would not only further the gap between rich and poor, but also cause a more controversial 
class divide. It could also eliminate certain physical traits and certain aspects of the human race 
around the world to create children with the “desired” traits. There would be no distributive 
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justice in this case. This is why it is imperative to set limits on this technology, the first being 
what it is used for. Genetic engineering technology like CRISPR-Cas9 and the like should be 
limited to use for disease control and elimination. It should not be allowed to use this technology 
for human enhancement (physical looks, intelligence, athleticism, etc.). This limitation 
essentially removes the main public fear of the use of any genetic engineering technology on 
human embryos. However, as humans created this technology and are furthering its development 
and use, is may be unrealistic to assume that these limitations would be set. 
 Along with this limitation comes the financial limitations. Although many aspects of the 
healthcare system are not equally fair among everyone who needs them, using the CRISPR-Cas9 
technology to prevent disease should be at least partially covered by private and public 
healthcare plans so that any member of the general public has the chance to save their future 
child from a fatal disease. This would allow justice within the healthcare system (in relation to 
genetic engineering), the greatest good for the greatest number of people, and a higher rate of 
disease elimination, which is the ultimate goal. Although these limitations and regulations of the 
technology could ethically justify its use on human embryos, and “that in the United States, there 
are [currently] piles of regulations to keep lab science from morphing into a genetically modified 
baby anytime soon,” the future cannot be accurately predicted and it is unknown whether 
limitations would be set once the technology reaches the necessary point for human use.79 
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VI. Conclusion 
 
In this thesis I attempted to explore the CRISPR-Cas9 genetic engineering system to 
modify the germline of human embryos in order to eliminate or alleviate Alzheimer’s disease. 
Through this exploration, I analyzed the specifics of the technology in its current state, the 
causes of Alzheimer’s disease, the scientific benefits and risks, and the ethical arguments for and 
against its use on humans. Through the explanations and arguments discussed in the previous 
section, I conclude that overall, it is not ethically justifiable to use the CRISPR-Cas9 technology 
to edit the germline, and therefore the hereditary material to be passed on to all future offspring, 
of a human embryo. 
As previously explained, the chapter on scientific benefits and risks, although the 
CRISPR-Cas9 system is the most developed engineering technology (and that which is closest to 
use on humans), it is not nearly perfected to the necessary point of accuracy in which it would 
not cause more harm than good. The possible side effects of complications like unintended base 
changes or mosaicism are unknown, and could possibly cause harm that far outweighs the 
benefit, for example, how it can cause cancer.80 The science behind the CRISPR-Cas9 
technology is still in a developmental stage when considering its use for human embryos. This 
conclusion is based on the analysis of multiple trials and case studies that have been performed 
by scientists and experts on genetic engineering across the world, none of which have been able 
to successfully edit out a gene from an inviable human embryo without any side effects in the 
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future (as none have observed the long-term effects or tried to use the CRISPR-Cas9 system on 
viable human embryos). 
Not only through the scientific risks, but the ethical arguments against the technology for 
use on humans also far outweighs the ethical arguments for the use of genetic engineering 
technology on human embryos. The technology violates the bioethical theories of deontology 
and consequentialism, as well as some of the four principles of medical ethics: justice, 
beneficence, and non-maleficence. The financial and low availability aspects of the clinical use 
of the technology do not allow for distributive justice, and create unfair gaps between those who 
can afford all expenses and those who cannot. As stated previously, the CRISPR-Cas9 genetic 
engineering system is considered to be “a slippery slope toward much more unacceptable 
uses.”81 There is a large fear of the creation of “designer babies,” which are superior children 
who have physical and possibly mental traits that were chosen before birth.82 This also creates 
the fear of a superior race, an elimination of certain traits of humans, and a larger gap between 
rich and poor. Using the CRISPR-Cas9 genetic engineering system on humans also violates 
different religious doctrines, as explained through the example of the Christian doctrine in 
chapter four. 
Even if the technology were developed to an almost perfect accuracy to where the 
scientific benefits outweigh the risks, the ethical arguments still would form the conclusion that 
overall, it is not ethically justifiable to use the CRISPR-Cas9 technology to edit the genetic 
makeup of a human embryo affecting its germline. The necessary limitations outlined in chapter 
four would need to be put in place in order to ethically justify CRISPR-Cas9 use on humans, and 
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as the future cannot be predicted, at this time it is still not ethically justifiable to use the 
CRISPR-Cas9 technology to edit the genetic makeup of a human embryo. However, once the 
CRISPR-Cas9 genetic engineering system reaches the scientific point for use on humans, we 
may see necessary limitations implemented and therefore the main fears of using genetic 
engineering on humans would be alleviated. It is not unlikely that it will be clinically used in the 
future for the benefit of the human race through the alleviation and possible elimination of 
Alzheimer’s disease, along with other genetically caused diseases and medical complications. 
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